View Single Post
Old 11-08-2021, 12:54 PM   #1
Pamelamary
Senior Member
 
Pamelamary's Avatar
 
Join Date: Apr 2012
Location: Melbourne, Australia
Posts: 494
Goodbye Herceptin?

Hi Everybody,
I have just found out that Australia's pharmaceutical benefits scheme will no longer be funding Roche's Herceptin and my treatment will continue with a "bio-similar" called Herzuma. Does anybody more technically minded than I know about this drug? I assume it should give me the same benefits and side effects, but need a little reassurance after nearly 10 years on Vitamin H.
Best wishes..... Pam
__________________
Diagnosed 2004: Lumpectomy - 2 tumours, both grade 1 infiltrating duct carcinoma, about 12mm. ER+,
C-erbB-2 status 3+.
Clear margins, no nodal involvement.
Radiotherapy, i year Tamoxifen, 4 years Arimidex.
Rediagnosed 2012: Multiple bone metastases.
3/12: began on Marianne trial - T-DM1 + Pertuzamab/Placebo.
5/12:Unexpected development of numerous bilateral liver mets. Came off trial.
Started Docetaxol/ Herceptin + Zometa.
8/12:Bones stable +major regression in liver (!)
9/12:Can't take any more Docetaxol! Start on Herceptin and Tamoxifen. Cross fingers!
Changed to Denosumab.
11/12: Scan shows stable - yay!
11/13: Still stable :-) !!!
1/16: All stable, but lowered calcium, so switched to Zometa 3 monthly.
2/19: Happily still stable on Herceptin, Letrozole and 3 monthly Zometa.
Pamelamary is offline   Reply With Quote